Recent Advances in Basic and Clinical Nanomedicine

Medical Clinics of North America

Volumn 91, Issue 5, 2007, Pages 805-843

  Morrow Jr , K John ^a   Bawa, Raj ^b,c,d   Wei, Chiming ^e  

^a Newport Biotechnology Consultants   (United States)

^b Bawa Biotechnology Consulting LLC   (United States)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^d NORTHERN VIRGINIA COMMUNITY COLLEGE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOSERTCAMPTOTHECIN; DENDRIMER; EPCAM ANTIBODY; INGN 401; LIPOSOME; MRX 952; PACLITAXEL; QUANTUM DOT; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VERIGENE; VIVAGEL;

ATTENTION; BREAST CANCER; CARDIOVASCULAR SYSTEM; COMMERCIAL PHENOMENA; DRUG DELIVERY SYSTEM; ENVIRONMENT; FLUORESCENCE RESONANCE ENERGY TRANSFER; FUNDING; GOVERNMENT; HAZARD; HEALTH CARE ORGANIZATION; HISTORY; INDUSTRY; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; METASTASIS; MOLECULAR DYNAMICS; NANOMEDICINE; NANOTECHNOLOGY; NANOTOXICOLOGY; NEUROLOGY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; RESEARCH; REVIEW; RISK; SAFETY; SOCIETY; SOLID TUMOR; WORKPLACE;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; NANOMEDICINE; NANOSTRUCTURES; PATENTS;

EID: 34548396196     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.05.009     Document Type: Review

References (117)

1. Feynman R.P. "There's plenty of room at the bottom.". Eng Sci (Caltech) 23 (1960) 22-36
2. Eric Drexler K. Nanosystems: molecular machinery, manufacturing, and computation (1992), John Wiley & Sons, New York
3. Report. Sizing nanotechnology's value chain (2004), Lux Research, New York
4. Webster P. World nanobiotechnology market (2005), Frost & Sullivan
5. Wolfe J., Paull R., and Herbert P. The nanotech report (2003), Lux Capital, New York
6. Nanobiotechnology, opportunities and technical analysis (2003), Front Line Strategic Consulting, San Mateo (CA)
7. Regaled A. Nanotechnology patents surge as companies vie to stake claim. Wall Str J (2004) section A1
8. Bawa R., Bawa S.R., Maebius S., et al. Bionanotechnology patents: challenges and opportunities. In: Bronzino J.D. (Ed). The biomedical engineering handbook. 3rd edition (2006), CRC Press, Boca Raton (FL) p. 29-16
9. Bawa R. Will the nanomedicine "patent land grab" thwart commercialization?. Nanomedicine 1 (2005) 346-350
10. Bawa R. Patenting inventions in nanomedicine: a catalyst for commercialization?. Small Times 5 8 (2005) 16
11. Bawa R. A comprehensive nanotechnology library in miniature: a review of the Springer Handbook of Nanotechnology. Nanotechnology Law Bus 1 (2004) 341-343
12. Bawa R., and Bawa S.R. Protecting new inventions in nanomedicine. In: Wagner C.G. (Ed). Foresight, innovation, and strategy: towards a wiser future (2005), World Future Society, Bethesda (MD) 31-44
13. Bawa R., Bawa S.R., Maebius S.B., et al. Protecting new ideas and inventions in nanomedicine via patents. Nanomedicine 1 2 (2005) 150-158
14. The Nanotech Report. 4th edition. "Key findings". Lux Research Inc., 2006. Available at: http://www.luxresearchinc.com/reference.html. Accessed June 1, 2006.
15. Forman D. IP storm clouds build on horizon. Small Times (2004) 21-24
16. Bawa R. Nanotechnology patenting in the US. Nanotechnology Law Bus 1 (2004) 31-50
17. Bawa R. Nanotechnology patents and the US Patent Office. Small Times 4 (2004) I P8. http://www.smalltimes.com/smallstage/images/ST_IP_Spec_Section.pdf Accessed May 10, 2006
18. Bawa R. Nanotechnology patents and challenges. Patent Cafe (2004). Available at: http://www.cafezine.com/index_article.asp?Id=10&deptid=3%20 Accessed May 10, 2006
19. Bawa R. Patents and Nanomedicine. Nanomedicine 2007;2(3):351-374.
20. Bawa R. The impact of the US Patent Office on nanotechnology. Available at: http://www.rpitechnology.com/?action=static&page=Resources. Accessed October 10, 2005.
21. Huang Z., Chen H., Yip A., et al. Longitudinal patent analysis for nanoscale science and engineering: country, institution and technology field. J Nanopart Res 5 (2003) 333-341
22. Bawa R., Bawa S.R., and Maebius S.B. The nanotechnology patent "gold rush". J Intellectual Property Rights 10 (2005) 426-433
23. Report. Nanotech's "second nature" patents: implications for the global south (2005), ETC Group, Ottawa (ON)
24. The nanotech land grab. Corp Leg Times 14 (2004) 34
25. Harris D., Miller J., Bawa R., et al. Strategies for resolving patent disputes over nanoparticle drug delivery systems. Nanotechnology Law Bus 1 (2004) 101-118
26. Stuart C., and Forman D. Nano startups consolidate IP positions. Small Times (2005). http://www.smalltimes.com Accessed October 5, 2005
27. Lawrence S. Patently absurd: too many patents could kill nanotechnology. Red Herring 119 (2002). http://www.redherring.com Accessed October 5, 2005
28. Sabety T. Nanotechnology innovation and the patent thicket: which IP policies promote growth?. Nanotechnol Law Bus 1 3 (2004) 262-283
29. Nanotechnology gold rush yields crowded, entangled patents (2004), Lux Research, New York. Available from: http://www.nanotech-now.com/news.cgi?story_id=09134 Accessed April 21, 2005
30. Miller J.C., Serrato R., Represas-Cardenas J.M., et al. Handbook of nanotechnology business, policy and intellectual property law (2004), Wiley, New York
31. Jaffe A.B., and Lerner J. Patent prescription: a radical cure for the ailing US patent system. IEEE Spectrum 42 (2005) 38-43
32. Report. To promote innovation: the proper balance of competition and patent law and policy (2003), Federal Trade Commission, Washington, DC
33. In: Merrill S.A., Levin R.C., and Myers M.B. (Eds). A patent system for the 21st century (2004), National Academies Press, Washington, DC
34. Stallman R. Are US patents too broad?. Science 297 (2002) 336
35. Gardner E. Patent pending. Corporate Counsel (2003) 104-107
36. Stopping madness at the PTO: improving patent administration through prosecution history estoppel. Harv Law Rev 116 (2003) 2164-2165
37. Paradise J., Andrews L., and Holbrook T. Patents on human genes: an analysis of scope and claims. Science 307 (2005) 1566-1567
38. Report. US Patent and Trademark Office: transforming to meet the challenges of the 21st century (2005), National Academy of Public Administration, Washington, DC
39. Brown D. US patent examiners may not know enough about nanotech. Small Times (2002). Available at: www.smalltimes.com Accessed Oct 1, 2005
40. Wild J. Patent challenges for nanotech inventions. Patent Cafe (2004). Available at: http://www.ipfrontline.com/printtemplate.asp?id=1487 Accessed Oct 1, 2005
41. Gruenwald J. Patent Office struggles to stay ahead of nanotech industry. Small Times (2004). http://www.smalltimes.com Accessed April 1, 2006
42. Hsieh T., Hack J., and Galvin L. Thinking small: the Patent Office grapples with nanotechnology. IP Law Bus (2003) 20-23
43. Acello R. Rules help Patent Office settle inventors' disputes. Small Times (2005) 14
44. Ainsworth S., and Nanotech I.P. Chem Eng News 82 15 (2004) 17-22
45. Serrato R., Hermann K., and Douglas C. The nanotech intellectual property (bIPQ) landscape. Nanotechnol Law Bus 2 2 (2005) 150-155
46. Shapiro C. Navigating the patent thicket: cross licenses, patent pools, and standard-setting. Innovation Policy Econ 1 (2000) 119-150
47. Drexler K.E. Engines of creation: the coming era of nanotechnology (1986), Anchor Books, New York
48. Fox S. Water based nanotech for the life sciences. Genet Eng News 25 21 (2005) 24-25
49. Rosi N.L., and Mirkin C.A. Nanostructures in biodiagnostics. Chem Rev 105 4 (2005) 1547-1562
50. Mittal A.K., and Kootz L.D. Improvements needed to better manage Patent Office automation and address workforce challenges. Report GAO-05-1008T (2005), United States Accountability Office, Washington, DC
51. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
52. Bawa R. Nanoparticle-mediated drug delivery. Touch Briefings, in press.
53. Brachet J. Cell biology and molecular biology. Adv Cytopharmacol 1 (1971) 1-12
54. Knudson A.G. A personal sixty-year tour of genetics and medicine. Ann Rev Genomics Hum Genet 6 (2005) 1-14
55. Fehr M., Ehrhardt D.W., Lalonde S., et al. Minimally invasive dynamic imaging of ions and metabolites in living cells. Curr Opin Plant Biol 7 3 (2004) 345-351
56. Michalet X., Pinaud F.F., Bentolila L.A., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307 5709 (2005) 538-544
57. Chan W.C.W. Bionanotechnology progress and advances. Biol Blood Marrow Transplant 12 (2006) 87-91
58. Pinaud F., Michalet X., Bentolila L.A., et al. Advances in fluorescence imaging with quantum dot bio-probes. Biomaterials 27 9 (2006) 1679-1687 [Epub Nov 28, 2005]
59. Lee J.H., Hwang K.S., Park J., et al. Immunoassay of prostate-specific antigen (PSA) using resonant frequency shift of piezoelectric nanomechanical microcantilever. Biosens Bioelectron 20 10 (2005) 2157-2162
60. Looger L.L., Lalonde S., and Frommer W.B. Genetically encoded FRET sensors for visualizing metabolites with subcellular resolution in living cells. Plant Physiol 138 2 (2005) 555-557
61. Fehr M., Takanaga H., Ehrhardt D.W., et al. Evidence for high-capacity bidirectional glucose transport across the endoplasmic reticulum membrane by genetically encoded fluorescence resonance energy transfer nanosensors. Mol Cell Biol 25 24 (2005) 11102-11112
62. Deuschle K., Okumoto S., Fehr M., et al. Construction and optimization of a family of genetically encoded metabolite sensors by semirational protein engineering. Protein Sci 14 9 (2005) 2304-2314
63. Freeman R.G., Raju P.A., Norton S.M., et al. Use of nanobarcodes particles in bioassays. Methods Mol Biol 303 (2005) 73-83
64. Yang H., and Kao W.J. Dendrimers for pharmaceutical and biomedical applications. J Biomater Sci Polym Ed 17 1-2 (2006) 3-19
65. Svenson S., and Tomalia D.A. Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev 57 15 (2005) 2106-2129
66. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A 93 10 (1996) 4897-4902
67. Moghimi S.M., and Agrawal A. Lipid-based nanosystems and complexes in experimental and clinical therapeutics. [editorial]. Curr Drug Deliv 2 4 (2005) 295
68. Service R.F. Calls rise for more research on toxicology of nanomaterials. Science 310 (2005) 1609
69. Sakamoto J.H., Smith B.R., Xie B., et al. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat 4 6 (2005) 627-636
70. Zheng G., Patolsky F., Cui Y., et al. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23 10 (2005) 1294-1301
71. Mirkin C.A., Thaxton C.S., and Rosi N.L. Nanostructures in biodefense and molecular diagnostics. Expert Rev Mol Diagn 4 6 (2004) 749-751
72. Kim S., Lim Y.T., Soltesz E.G., et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22 (2003) 93-97
73. Alivisatos A.P. Semiconductor clusters, nanocrystals, and quantum dots. Science 271 (1996) 933-937
74. Chen W. Fluorescence, thermoluminescence, and photostimulated luminescence of nanoparticles. In: Nalwa H.S. (Ed). Handbook of nanostructured materials and nanotechnology (2000), Academic Press, San Diego (CA) 325-392
75. Chen W., Joly A.G., and Wang S. Luminescence of semiconductor nanoparticles. In: Nalwa H.S. (Ed). Encyclopedia of nanoscience and nanotechnology (2003), American Scientific Publishers, Stevenson Ranch (CA)
76. Akerman M.E., Chan W.C.W., Laakkonen P., et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99 (2002) 12617-12621
77. Kershaw S.V., Burt M., Harrison M., et al. Colloidal CdTe/HgTe quantum dots with high photoluminescence quantum efficiency at room temperature. Appl Phys Lett 75 (1999) 1694-1696
78. Harrison M.T., Kershaw S.V., Burt M.G., et al. Wet chemical synthesis and spectroscopic study of CdHgTe nanocrystals with strong near-infrared luminescence. Materials Science and Engineering B-Solid State Materials for Advanced Technology 69 (2000) 355-360
79. Morgan N.Y., English S., Chen W., et al. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol 12 (2005) 313-323
80. Kukowska-Latallo J.F., Candido K.A., Cao Z., et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65 12 (2005) 5317-5324
81. Fritz J., Baller M.K., Lang H.P., et al. Translating biomolecular recognition into nanomechanics. Science 288 5464 (2000) 316-318
82. McKendry R., Zhang J., Arntz Y., et al. Multiple label-free biodetection and quantitative DNA-binding assays on a nanomechanical cantilever array. Proc Natl Acad Sci U S A 99 15 (2002) 9783-9788 [Epub Jul 15, 2002]
83. Morrow K.J. Nanotechnology: applications to biotechnology. Genomic/Proteomic Technology 2 6 (2002) 26-29
84. Hansen K.M., and Thundat T. Microcantilever biosensors. Methods 37 1 (2005) 57-64 [Epub Sep 30, 2005]
85. Backmann N., Zahnd C., Huber F., et al. A label-free immunosensor array using single-chain antibody fragments. Proc Natl Acad Sci U S A 102 41 (2005) 14587-14592 [Epub Sep 28, 2005]
86. Mukhopadhyay R., Lorentzen M., Kjems J., et al. Nanomechanical sensing of DNA sequences using piezoresistive cantilevers. Langmuir 21 18 (2005) 8400-8408
87. Wee K.W., Kang G.Y., Park J., et al. Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers. Biosens Bioelectron 20 10 (2005) 1932-1938
88. Lee N.K., Kapanidis A.N., Wang Y., et al. Accurate FRET measurements within single diffusing biomolecules using alternating-laser excitation. Biophys J 88 4 (2005) 2939-2953
89. Roby A., Erdogan S., and Torchilin V.P. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 62 3 (2006) 235-240
90. Kaul G., and Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res 22 6 (2005) 951-961
91. Huang X., El-Sayed I.H., Qian W., et al. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 128 6 (2006) 2115-2120
92. Liu P., Konstam M.A., and Force T. Highlights of the 2004 scientific sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004. J Am Coll Cardiol 45 4 (2005) 617-625
93. Cyrus T., Winter P.M., Caruthers S.D., et al. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther 3 4 (2005) 705-715
94. Becarevic M., Andrejevic S., Bonaci-Nikolic B., et al. Anti-oxLDL antibodies-marker for arterial thromboses in antiphospholipid syndrome?. Clin Lab 51 5-6 (2005) 279-283
95. Zoghlami-Rintelen C., Vormittag R., Sailer T., et al. The presence of IgG antibodies against beta 2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 3 6 (2005) 1160-1165
96. Stevens S.M., Gregory Elliott C., Woller S.C., et al. The use of a fixed high sensitivity to evaluate five D-dimer assays' ability to rule out deep venous thrombosis: a novel approach. Br J Haematol 131 3 (2005) 341-347
97. Ozeren M., Karahan S.C., Ozgur M., et al. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1. Acta Obstet Gynecol Scand 84 10 (2005) 987-991
98. Katsumata S., Nagashima M., Kato K., et al. Changes in coagulation-fibrinolysis marker and neutrophil elastase following the use of tourniquet during total knee arthroplasty and the influence of neutrophil elastase on thromboembolism. Acta Anaesthesiol Scand 49 4 (2005) 510-516
99. Fancher T.L., White R.H., and Kravitz R.L. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 329 7470 (2004) 821-829
100. Chen Y.P., O'Toole T.E., Leong L., et al. Beta 3 integrin-mediated fibrin clot retraction by nucleated cells: differing behavior of alpha IIb beta 3 and alpha v beta 3. Blood 86 7 (1995) 2606-2615
101. Malinski T. Understanding nitric oxide physiology in the heart: a nanomedical approach. Am J Cardiol 96 7B (2005) 13i-24i [Epub Aug 8, 2005]
102. Meng J., Kong H., Xu H.Y., et al. Improving the blood compatibility of polyurethane using carbon nanotubes as fillers and its implications to cardiovascular surgery. J Biomed Mater Res A 74 2 (2005) 208-214
103. Freitas R. Robots in the bloodstream: the promise of nanomedicine. 2005. Available at: www.kurzweillai.net/meme/frame.html?main =/art0410.html.
104. Silva G.A. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol 63 4 (2005) 301-306
105. Blass J.P. Cerebrometabolic abnormalities in Alzheimer's disease. Neurol Res 25 (2003) 556-566
106. Dugan L.L., Lovett E.G., Quick K.L., et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord 7 3 (2001) 243-246
107. Okumoto S., Looger L.L., Micheva K.D., et al. Detection of glutamate release from neurons by genetically encoded surface-displayed FRET nanosensors. Proc Natl Acad Sci U S A 102 24 (2005) 8740-8745
108. Kandel E.R. The molecular biology of memory storage: a dialogue between genese and synapses. Science 294 (2001) 1030-1038
109. Rothstein J.D. Excitotoxicity hypothesis. Neurol 47 (1996) S19-S26
110. Haes A.J., Chang L., Klein W.L., et al. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127 7 (2005) 2264-2271
111. Ghribi O. The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease. Curr Mol Med 6 1 (2006) 119-133
112. Maynard A.D., and Kuempel E. Journal of Nanoparticle Research 7 (2005) 587-614
113. Barlow P.G., Clouter-Baker A., Donaldson K., et al. Carbon black nanoparticles induce type II epithelial cells to release chemotaxins for alveolar macrophages. Part Fibre Toxicol 2 1 (2005) 11
114. Bullis K. Monitoring complex new nanotech materials may be too much for the agency to handle. MIT Technology Review (2005)
115. Cleveland P. Nanotec: the best is yet to come. InMfg (2005 November) 34-37
116. Goldstein AH. Nanomedicine's brave new world. 2005. Available at: http://www.salon.com/tech/feature/2005/11/28/nanomedicine/print.html.
117. Unicef. Statistical Tables. Available at: http://www.unicef.org/sowc05/english/statistics.html.